Evidence map›Paper›PMID 42182802›Full record

ArticleJournal of thoracic disease2026

Segmentectomy achieves comparable survival outcomes compared to lobectomy in peripheral ≤3 cm non-small cell lung cancer with occult lymph node metastases.

Yuting Chen, Jie Wang, Xusheng Ding, Chunnan Liu, Yueren Yan, Yifu Sun, Chongze Yuan, Shanbo Zheng, Longlong Shao, Yunjian Pan and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yuting Chen *Department of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID https://orcid.org/0009-0003-7741-9547
Jie Wang *Department of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Xusheng Ding *Department of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Chunnan LiuDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Yueren YanDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Yifu SunDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Chongze YuanDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Shanbo ZhengDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Longlong ShaoDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Yunjian PanDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Hang LiDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Yiliang ZhangDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiaoyang LuoDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Yawei ZhangDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Jiaqing XiangDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Hong HuDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Yihua SunDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID https://orcid.org/0000-0002-5287-0601

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: While lobectomy remains the standard surgical approach for ≤3 cm non-small cell lung cancer (NSCLC), growing evidence suggests that segmentectomy offers comparable survival outcomes. However, whether segmentectomy provides similar prognostic benefit in patients with occult lymph node metastases remains unclear. This study aimed to compare the survival outcomes of segmentectomy versus lobectomy in peripheral ≤3 cm NSCLC patients with pathologically confirmed occult lymph node metastases. Methods: We retrospectively analyzed data of peripheral ≤3 cm cN0 NSCLC patients with pathologically confirmed pN1/2 disease treated at Shanghai Cancer Center between 2015 and 2023. Patients were categorized into segmentectomy and lobectomy groups. After 1:2 nearest-neighbor propensity score matching (PSM), clinical and prognostic outcomes were compared between the groups. Results: A total of 363 patients were included, and after 1:2 nearest-neighbor PSM, 71 patients who underwent segmentectomy and 112 who underwent lobectomy were selected for further study. Survival analysis showed no significant difference between the two groups in overall survival (P=0.53) and recurrence-free survival (P=0.78). Upon further investigation, subgroup analyses revealed no significant differences in survival across most clinical variables. Conclusions: Among patients with tumors ≤3 cm and occult lymph node metastases, segmentectomy can achieve survival outcomes comparable to lobectomy. These findings suggest that segmentectomy may be a viable surgical alternative in appropriately selected NSCLC patients with occult nodal involvement.

Indexed as

lobectomyNon-small cell lung cancer (NSCLC)occult lymph node metastasessegmentectomy

Identifiers

PMID42182802
PMCPMC13190037

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.